Surgical Excision is NOT a Standard Treatment for Prurigo Nodularis
Surgical excision is not recommended as a primary or standard treatment modality for prurigo nodularis (PN). While one small case series from 1983 reported success with cryosurgery combined with intralesional steroids 1, no contemporary guidelines or systematic reviews support surgical excision as an appropriate therapeutic approach for this condition.
Why Surgery is Inappropriate for PN
PN is a chronic inflammatory skin disease characterized by intensely pruritic nodular lesions driven by a neuroimmune feedback loop involving type 2 inflammation (IL-4, IL-13, IL-31), Th17/Th22 pathways, and neural dysregulation 2. The pathophysiology involves:
- Inflammatory cytokine dysregulation throughout affected and unaffected skin
- Neuronal hyperplasia and sensitization in the dermis
- A self-perpetuating itch-scratch cycle
- Multiple lesions distributed across body surfaces (lower extremities in 93%, upper extremities in 69% of patients) 3
Surgical excision cannot address the underlying systemic inflammatory and neural mechanisms driving PN. Removing individual nodules would be:
- Impractical given the typically multifocal distribution
- Ineffective at breaking the itch-scratch cycle
- Unable to prevent new lesion formation
- Potentially disfiguring with multiple scars
Evidence-Based Treatment Approach
First-Line Therapy
Dupilumab (anti-IL-4/IL-13) is the only FDA-approved treatment and should be considered first-line for moderate-to-severe PN 4, 5. At 24 weeks, dupilumab achieved:
- 58-59% of patients with clinically meaningful itch improvement (vs. 18-21% placebo)
- 42-52% achieving clear/almost clear skin (vs. 16-18% placebo)
- Significant improvements in quality of life, sleep, and mental health outcomes
- Efficacy regardless of atopic comorbidity status 5
Alternative Systemic Options
When dupilumab is unavailable or contraindicated, consider 6, 7, 3:
Moderate evidence (Level 2b or higher):
- Cyclosporine: 38% significant pruritus improvement at 16 weeks 3
- Methotrexate: 31% significant improvement at 16 weeks 3
- Thalidomide: Good symptom response but limited by neuropathy risk with long-term use 6, 7
- Pregabalin: Effective for neural component but limited by muscle/nerve pain 7
Emerging therapies:
- Nemolizumab (anti-IL-31 receptor A): Positive phase III data 2
- JAK inhibitors (abrocitinib, povorcitinib, ruxolitinib): In phase II-III trials 2
Adjunctive Therapies
- Phototherapy (NB-UVB): 35% improvement at 16 weeks; useful for widespread disease 3
- Topical corticosteroids and calcineurin inhibitors: All studies showed beneficial effects (Level 2b evidence) 6
- Intralesional corticosteroids: May be considered for isolated resistant nodules but showed only 44% complete response and required multiple injections 8
Clinical Pitfalls to Avoid
- Do not treat PN as a purely dermatologic problem requiring local destruction—it requires systemic immunomodulation
- Do not overlook comorbidities: 79% have mental health disorders (58% depression, 52% anxiety); atopic dermatitis, diabetes, and chronic kidney disease are common 3, 9
- Do not delay diagnosis: Mean age at diagnosis is 50 years, but delayed recognition worsens disease burden and quality of life 9
- Combination therapy may be necessary to target both immune and neural components simultaneously 4
Specific Indications Where Excision Might Be Considered
The only theoretical scenario where surgical intervention could be justified:
- Diagnostic uncertainty requiring histopathology to exclude malignancy (squamous cell carcinoma, lymphoma) in an atypical solitary nodule
- This would be diagnostic excision, not therapeutic excision
Even in this scenario, a punch biopsy would be more appropriate than formal excision.